<DOC>
	<DOCNO>NCT00005920</DOCNO>
	<brief_summary>The purpose study see safe effective give L-743,872 patient thrush , AIDS-related yeast infection mouth , cure fluconazole treatment .</brief_summary>
	<brief_title>Safety Effectiveness Giving L-743,872 Patients With Thrush That Has Not Been Cured With Fluconazole</brief_title>
	<detailed_description>Patients randomize treatment L-743,872 one two dos administer intravenously peripheral line once-daily . Patients treat 48 hour beyond resolution symptom maximum 14 day . Each patient expect complete study , include 14-day follow-up , within approximately 4 week . A physical examination perform daily antifungal treatment period follow-up visit 7 14 day post-therapy . Laboratory test blood urine safety perform every three day treatment follow-up 7 day post-therapy . Liver enzymes draw 14-day follow-up visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Oral</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Have thrush respond fluconazole treatment . Are 1865 year old .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Candidiasis , Oral</keyword>
	<keyword>Pharyngeal Diseases</keyword>
	<keyword>MK 0991</keyword>
</DOC>